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ibronectins (FNs) are multifunctional high molecular
weight glycoproteins present in the blood plasma and
in the ECMs of tissues. The FN primary transcript under-
goes alternative splicing in three regions generating up to
20 main different variants in humans. However, the precise
role of the FN isoforms is poorly understood. One of the
alternatively spliced exons is the extra domain A (EDA) or
extra type III homology that is regulated spatially and
temporally during development and aging. To study its in
vivo function, we generated mice devoid of EDA exon-
regulated splicing. Constitutive exon inclusion was obtained
by optimizing the splice sites, whereas complete exclusion
was obtained after in vivo CRE-loxP–mediated deletion of
F
 
the exon. Homozygous mouse strains with complete exclu-
sion or inclusion of the EDA exon were viable and developed
normally, indicating that the alternative splicing at the EDA
exon is not necessary during embryonic development.
Conversely, mice without the EDA exon in the FN protein
displayed abnormal skin wound healing, whereas mice
having constitutive inclusion of the EDA exon showed a
major decrease in the FN levels in all tissues. Moreover,
both mutant mouse strains have a signiﬁcantly shorter
lifespan than the control mice, suggesting that EDA splicing
regulation is necessary for efﬁcient long-term maintenance
of biological functions.
 
Introduction
 
Fibronectins (FNs)* are high molecular weight glycoproteins
that are present on many cell surfaces, in extracellular fluids,
connective tissues, and basement membranes. They interact
with other ECM proteins and cellular ligands, such as gly-
cosaminoglycans, collagen, fibrin, and integrins (Kornblihtt
and Gutman, 1988; Hynes, 1990). FNs play key roles in the
adhesive and migratory behavior of cells related to funda-
mental processes such as embryogenesis, malignancy, hemo-
stasis, wound healing, host defense, and maintenance of tissue
integrity (Hynes, 1990; ffrench-Constant, 1995; Kornblihtt
et al., 1996). FN molecules are a mixture of several protein
types that differ in both their primary structure and post-
translational modifications. The amino acid sequence variations
are the consequence of the alternative processing of a single
primary transcript at three sites: extra domain B (EDB) or
extra type III homology B (also called EIII-B or EDII), extra
domain A (EDA [EIII-A or EDI]) and type III homologies
connecting segment (IIICS; V region in rat). The alternative
splicing process is cell type-, developmentally, and age regu-
lated. The EDA and EDB are single exons coding for single
type III repeats that are included or excluded from the FN
mRNA by exon skipping (Kornblihtt et al., 1984; Gutman
and Kornblihtt, 1987; Schwarzbauer et al., 1987; Zardi et
al., 1987). The IIICS region undergoes a more complex pattern
of splicing which is species dependent (Schwarzbauer et al.,
1983). In humans, over 20 main different isoforms are gen-
erated after mRNA processing, whereas in rats and mice, 12
variants are produced (ffrench-Constant, 1995; Kornblihtt
et al., 1996). Two major forms of FN exist, plasma (pFN)
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and cellular (cFN), having similar but not identical polypep-
tides of 
 
 
 
220–240 kD. pFN is a soluble dimeric form that
lacks both the EDA and EDB domains. It is synthesized by
hepatocytes and secreted into the bloodstream. cFN is a
dimeric or cross-linked multimeric form containing the
EDA and EDB domains at variable proportions. It is made
by fibroblasts, epithelial, and other cell types, and is depos-
ited as fibrils in the ECM (Hynes, 1990; ffrench-Constant,
1995; Kornblihtt et al., 1996).
The molecular mechanisms involved in processing the FN
transcript are well understood for both the EDA and EDB
exons (Mardon et al., 1987; Lavigueur et al., 1993; Caputi
et al., 1994; Du et al., 1997; Lim and Sharp, 1998; Muro et
al., 1999). The mouse EDA exon is regulated in a similar
manner to its human counterpart and optimization of the 5
 
 
 
and 3
 
 
 
 splice junctions of the exon leads to constitutive
splicing in NIH3T3 cells (Muro et al., 1998).
Despite the fact that both FN primary structure and FN
alternative splicing were described almost two decades ago
(Kornblihtt et al., 1983; Petersen et al., 1983; Schwarz-
bauer et al., 1983; Kornblihtt et al., 1984; Zardi et al.,
1987), many aspects of the function of FN isoforms remain
elusive. In vivo studies in chicken, rat, and 
 
Xenopus
 
 showed
the increased inclusion of EDA and EDB exons in the
FN mRNA derived from embryos during development
(ffrench-Constant and Hynes, 1989; Oyama et al., 1989;
Pagani et al., 1991; DeSimone et al., 1992). Once develop-
ment is complete, the inclusion of EDA and EDB decreases
in a wide range of tissues. In fact, EDA
 
 
 
 and EDB
 
 
 
 forms
are the most abundant forms in adult humans and rats
(Magnuson et al., 1991; Pagani et al., 1991). This exclusion
is cell type specific and differs in extent between the two ex-
ons. Quantitative mRNA studies in these tissues showed
that the EDB exon is excluded more often than the EDA
exon from the FN mRNA (ffrench-Constant and Hynes,
1989; Pagani et al., 1991; Caputi et al., 1995). It has been
postulated that the inclusion of the spliced regions could al-
ter the conformation of the RGD sequence, which is the
main cell-binding site, via modification of its neighboring
modules (ffrench-Constant, 1995) or by the alteration of
the global conformation of the FN molecule (Manabe et
al., 1997). In both cases, the alteration might affect the
strength of the central cell–binding domain interaction
with integrins. Since integrins 
 
 
 
9
 
 
 
1
 
 and 
 
 
 
4
 
 
 
1
 
 were recently
described as the cellular receptors for the EDA segment, an-
other possibility is that cell adhesion can be directly regu-
lated by alternative splicing (Liao et al., 2002). Other func-
tions proposed for the EDA segment are as follows: wound
healing (Clark et al., 1983; ffrench-Constant et al., 1989);
matrix assembly (Guan et al., 1990); dimer formation (Pe-
ters et al., 1990); secretion (Wang et al., 1991); cell adhe-
sion (Xia and Culp, 1995); cell differentiation (Jarnagin et
al., 1994); tissue injury and inflammation (Satoi et al.,
1999; Okamura et al., 2001); and cell cycle progression and
mitogenic signal transduction (Manabe et al., 1999). Be-
cause most of the above studies were done using in vitro
and cell culture systems, the in vivo role of the EDA seg-
ment still remains obscure. The use of mouse models could
provide the best approach to understand the in vivo func-
tion of the EDA exon. However, the in vivo study of the
function of the different protein isoforms is complex due to
the simultaneous presence of more than one protein form at
a given specific developmental time and tissue. Gene target-
ing in mice has allowed the specific deletion of alternatively
spliced exons in different protein systems such as 
 
 
 
6
 
 inte-
grin, 
 
 
 
-aminobutyrate receptor, dopamine D2 receptor,
FN, Pax6, and Stat3 (Gimond et al., 1998; Homanics et al.,
1999; Usiello et al., 2000; Wang et al., 2000; Fukuda et al.,
2002; Singh et al., 2002; Yoo et al., 2002). Thus, it repre-
sents the best approach to understand the in vivo function
of the EDA exon.
Taking advantage of our detailed knowledge of the ele-
ments involved in EDA splicing regulation (Mardon et al.,
1987; Caputi et al., 1994; Muro et al., 1998, 1999), we
have designed a novel approach to study the in vivo func-
tion of protein isoforms coded by genes that undergo alter-
native splicing without modifying the coding sequence of
the FN gene. Using gene targeting, we generated a mouse
strain containing the EDA allele with optimized splice sites
at both splicing junctions (EDA
 
 
 
 allele), with loxP sites lo-
cated in the adjacent introns. By mating this mouse strain
with a “deleter” CRE-recombinase expressing mouse, an
EDA-null allele was obtained (EDA
 
 
 
 allele). Here, we show
that FN mRNA produced by homozygous EDA
 
 
 
/
 
 
 
 mice
contained constitutive inclusion of the EDA exon devoid of
developmental and tissue-specific regulation. Mice lacking
EDA splicing regulation (EDA
 
 
 
/
 
 
 
 and EDA
 
 
 
/
 
 
 
) were via-
ble and phenotypically similar to the wild-type mice. How-
ever, the mouse strain producing EDA
 
 
 
 FN showed an ab-
normal cutaneous skin wound healing. On the other hand,
mice having the EDA exon constitutively included in the
FN mRNA showed normal wound healing but had a strik-
ing decrease in the levels of FN in most of the organs ana-
lyzed from adult mice. Furthermore, and most importantly,
both mouse strains had a significantly shorter lifespan than
EDA
 
wt/wt
 
 animals, suggesting that the presence of both iso-
forms was necessary for efficient long-term maintenance of
biological functions.
 
Results
 
The study of the in vivo function of protein isoforms gener-
ated by alternatively spliced genes is generally limited by the
fact that the different isoforms coexist in a temporal and spa-
tial manner in the same tissue of the organisms. Therefore,
the availability of animal models having a controlled expres-
sion of the different forms is crucial for these studies.
We have previously reported that optimization of the 5
 
 
 
and 3
 
 
 
 splicing sites of the mouse EDA exon from the FN
gene leads to constitutive exon inclusion in NIH3T3 cells
(Muro et al., 1998). These results coupled with the power
of homologous recombination technology in mouse em-
bryonic stem (ES) cells enabled us to study the biological
significance of protein isoforms generated by alternative
splicing (for a detailed description of the rationale see On-
line supplemental material available at http://www.jcb.org/
cgi/content/full/jcb.200212079/DC1). Furthermore, to
date, there is no report of optimization of splice sites lead-
ing to constitutive splicing in vivo of a natural alternatively
spliced exon.T
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Mouse strains lacking alternative splicing at the EDA 
exon develop normally and are fertile
 
To generate an FN allele devoid of alternative splicing in the
EDA exon, the wild-type EDA exon in the FN gene was re-
placed with a “floxed” EDA exon having both the 5
 
 
 
 and 3
 
 
 
optimized splice sites described in Fig. S1 (available at http:
www.jcb.org/cgi/content/full/jcb.200212079/DC1). After
electroporation of 129 Sv/J ES cells with the targeting con-
struct (Fig. 1 A), G418-resistant clones were selected and
analyzed by Southern blot hybridization. A second step of
recombination by transient expression of the CRE-recombi-
nase was performed to eliminate the Neo-TK cassette from
the EDA-flanking intron. Southern blot analysis and se-
 
quencing of the PCR-amplified genomic EDA region con-
firmed the introduction of the optimized 3
 
 
 
 and 5
 
 
 
 splice
sites and the loxP sites flanking the EDA exon in one of the
FN alleles. Hereafter, this allele will be called the EDA
 
 
 
 al-
lele. The heterozygous EDA
 
 
 
/wt
 
 ES cells were used to obtain
male chimeras that transmitted the EDA
 
 
 
 allele to the germ-
line. Heterozygous EDA
 
 
 
/wt
 
 mice were mated with CMV-
CRE-transgenic mice to obtain the EDA-null allele (hence-
forth, called the EDA
 
 
 
 allele) after in vivo deletion of the
loxP-flanked EDA exon. Homozygous mice were obtained
by interbreeding heterozygous mice, and screening was per-
formed by Southern blot analysis (Fig. 1 B) or by PCR of
tail DNA biopsies (not depicted).
The homozygous EDA
 
 
 
/
 
 
 
 and EDA
 
 
 
/
 
 
 
 mice after birth ex-
hibited no apparent developmental abnormalities compared
with wild-type or heterozygous littermates; they reached
adulthood and were fertile. In addition, no differences were
detected in the organs from homozygous EDA
 
 
 
/
 
 
 
 and EDA
 
 
 
/
 
 
 
mice by gross histological and pathological analysis (unpub-
lished data). The mutated alleles segregated at the expected
Mendelian frequency, and litter size and survival rate of new-
born mice (measured until weaning of the litter) were similar
to that of EDA
 
wt/wt
 
 animals. No differences were observed nei-
ther in the shape of the embryos nor in the number of somites
of embryos derived from timed matings. The detailed data are
shown in the Online supplemental material section.
 
EDA
 
 
 
/
 
 
 
 mice lack alternative splicing of the EDA exon
 
The inclusion of the EDA exon within the FN mRNA is sub-
jected to a tight tissue-specific regulation. The most dramatic
example is seen in liver, where pFN is synthesized and the
EDA exon is completely excluded from the mRNA in the
adult (Tamkun and Hynes, 1983; Kornblihtt et al., 1984).
Radioactive RT-PCR was used to analyze most of the tis-
sues and organs in all three genotypes (EDA
 
wt/wt
 
, EDA
 
 
 
/
 
 
 
,
and EDA
 
 
 
/
 
 
 
). An example of the EDA splicing pattern in
representative tissues such as liver, brain, and kidney is
shown in Fig. 1 C. These results were confirmed by RNase
protection analysis of the same samples (Fig. S2 available
at http:www.jcb.org/cgi/content/full/jcb.200212079/DC1).
We observed that the EDA
 
 
 
 form was never present in the
samples from EDA
 
 
 
/
 
 
 
 mice and the EDA
 
 
 
 product from
EDA
 
 
 
/
 
 
 
 mice was present in all tissues. Both RNase protec-
tion and RT-PCR analysis of the FN mRNAs showed that
there is 99–100% inclusion of the EDA exon in all tissues
from EDA
 
 
 
/
 
 
 
 mice, whereas there is 100% EDA exon ex-
clusion in all tissues belonging to the EDA
 
 
 
/
 
 
 
 mice. This
confirmed that the rationale of genetic modification was
successfully fulfilled in the real in vivo situation.
 
Normal FN-ECM formation in mouse embryonic 
fibroblasts (MEF) derived from mice lacking 
regulated splicing at the EDA exon
 
Next, we examined the expression of FN mRNA, protein iso-
forms and ECM formation in MEF prepared from EDA
 
wt/wt
 
,
EDA
 
 
 
/
 
 
 
, and EDA
 
 
 
/
 
 
 
 animals. RT-PCR analysis confirmed
the constitutive splicing-in of the EDA exon in the EDA
 
 
 
/
 
 
 
and its absence in the EDA
 
 
 
/
 
 
 
 MEFs (Fig. 2 A). Analysis of
protein extracts by Western blot using polyclonal anti-FN
Figure 1.  Strategy for the generation of mouse strains lacking 
regulated splicing at the EDA exon of the FN gene. (A) Partial maps 
of the wild-type FN allele, the targeting vector, the targeted allele, 
the EDA-floxed allele, and the EDA-null alleles. Exons, Neo-TK, and 
DTA are shown as gray, white, and dotted boxes, respectively. The 
EDA exon and the “loxP” sites are indicated as a black square and 
as white triangles, respectively. N and H indicate NcoI and HindIII 
sites, respectively. The recombinant ES cells were transiently 
transfected with a CRE-recombinase expressing plasmid, and EDA
 /wt 
heterozygote cells were used for blastocyst microinjection. EDA
 /wt 
mice were mated with a CRE-expressing transgenic mouse strain to 
obtain the EDA
 /wt mice. The asterisks indicate the NdeI sites. The 
4.0-, 2.7-, and 2.0-kb DNA fragments (EDA
wt, EDA
 , and EDA
  
alleles, respectively) obtained after digestion with HindIII and 
Southern blot hybridization with the internal probe are indicated. 
(B) Southern blot screening of the different mouse genotypes. EDA
wt, 
EDA
 ,
 and EDA
  bands are indicated. (C) RT-PCR analysis of total 
RNA prepared from EDA
wt/wt, EDA
 / ,
 and EDA
 /  from liver, brain, 
and kidney is shown. EDA
  and EDA
  bands are indicated (805 and 
535 bp, respectively).T
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and monoclonal anti-EDA antibodies showed normal pro-
tein levels in both the EDA
 
 
 
/
 
 
 
 and EDA
 
 
 
/
 
 
 
 MEF (Fig. 2 B).
The anti-EDA antibody detected the EDA
 
 
 
 FN isoform only
in EDA
 
 
 
/
 
 
 
 and EDA
 
wt/wt
 
 MEF (Fig. 2 C).
Immunofluorescence analysis using a confocal microscope
showed the presence of a normal FN-ECM in EDA
 
 
 
/
 
 
 
 and
EDA
 
 
 
/
 
 
 
 MEF when compared with EDA
 
wt/wt
 
 MEF (Fig. 2
D). The signal obtained with the anti-EDA antibody colo-
calized with that observed with the anti-FN antibody.
 
Ablation of regulated splicing in the EDA exon 
produced a decrease in FN levels in EDA
 
 
 
/
 
 
 
 mice 
that did not correlate to changes neither in FN mRNA 
nor in the integrin levels
 
Next, we examined whether the modifications in the natural
alternative splicing pattern of FN had some consequences in
other cellular proteins or FN itself. Consequently, protein
extracts from different tissues of the different genotypes were
Figure 2.  Regulated splicing of the 
EDA is dispensable for the ECM 
formation. (A) RT-PCR analysis of total 
RNA prepared from MEF from EDA
wt/wt, 
EDA
 / , and EDA
 /  embryos (13.5 d 
postcoitus [p.c.]). (B and C) Western 
blot analysis of protein extracts prepared 
from the above-described MEF (20 and 
100  g for B and C, respectively) with 
anti-FN and anti-EDA antibodies, 
respectively. Coomassie blue staining 
showed equal loading. (D) MEF prepared 
from EDA
wt/wt, EDA
 / , and EDA
 /  
embryos (13.5 d p.c.) were plated, fixed, 
and incubated with anti-EDA antibody 
(left column) or with anti–total FN 
antibody (middle column). The merged 
image is shown in the right column.
Figure 3.  The decrease in FN levels in tissues of EDA
    
mice is not correlated to a reduction in integrin levels. 
(A and B) Western blot analysis of total protein extracts 
(50  g) from brain, heart, lung, and liver from all genotypes 
(EDA
wt/wt, EDA
 / , EDA
 / , EDA
 / , EDA
 /wt, and EDA
 /wt) 
using anti-FN polyclonal antibody (A) and, after stripping 
the membrane, anti– -tubulin mAb to verify for minor 
errors in protein load (B). Note that the migration of the 
EDA
  FN is slightly slower than that of the EDA
  FN. 
Coomassie blue staining of 5–17% gradient gels of the 
same protein extracts did not show changes in other 
proteins. (C) Plasma and serum protein samples from 
EDA
 / , EDA
 / , and EDA
wt/wt mice (20  g) were Coomassie 
blue stained (left), and a similar gel was blotted and 
incubated with anti-FN antibody (middle). For the anti-EDA 
antibody (right), 100  g of protein extract were loaded. 
(D and E) Western blot analysis of  9- and  1-integrin 
levels in different tissues (liver, brain, and skin) using 
anti- 9 and - 1 rabbit polyclonal antibodies. Anti– -tubulin 
mAb was used to verify for minor errors in protein load.T
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prepared from 3-mo-old mice and analyzed by SDS-PAGE.
No evident difference was observed at least at the sensitivity
level of Coomassie blue staining of 5–17% gradient gels (un-
published data). On the other hand, a Western blot analysis
using anti-FN polyclonal antibody showed a striking de-
crease in FN levels in most of the tissues analyzed from
EDA
 /  mice (Fig. 3 A). This decrease was also evident in
EDA
 /wt and EDA
 /  mice, both bearing one EDA
  allele.
The observed differences were not due to a different protein
load of the gels, as evidenced by the Coomassie blue staining
and by the incubation of the same membranes with an anti–
 -tubulin mAb (Fig. 3 B). A significant decrease in FN
amounts was also observed in the plasma and serum samples
prepared from EDA
 /  animals when compared with those
from EDA
wt/wt mice (Fig. 3 C). Western blot using an anti-
EDA antibody confirmed the presence of EDA containing
FN in the EDA
 /  plasma and its complete absence in the
EDA
 /  sample (Fig. 3 C).
It was considered important to analyze if the FN level dif-
ferences observed in the different tissues were associated to
changes in the levels of the specific EDA receptor  9 1-inte-
grin (Liao et al., 2002). We observed no differences in  9-
and   1-integrin levels among EDA
wt/wt, EDA
 / , and
EDA
 /  mice by Western blot analysis in liver and brain
(Fig. 3 D). However, it remains to be seen if the localization
pattern of the integrin receptors or their signaling have been
affected in the mutant mice.
On the other hand, to determine whether the observed
decrease in FN protein levels in the EDA
 /  mice was corre-
lated to a decrease in the mRNA levels, we performed
Northern blot analysis of total RNA isolated from the tissues
having the higher decrease in FN levels (brain and heart)
from 3-mo-old male mice. No significant variations were
Figure 4.  Expression of FN in different tissues at different ages. 
(A) Protein extracts from liver, heart, lung, and brain were prepared 
from EDA
wt/wt, EDA
 / , and EDA
 /  mice of different ages (13.5 d 
p.c., 1, 3, and 14 mo old) and analyzed by Western blot using an 
anti-FN antibody. (B) The histograms represent the relative amount 
of FN present in EDA
 /  mice relative to that present in EDA
wt/wt 
mice (considered as 100%) for each tissue and each time point.
Figure 5.  Reepithelization is observed 5 d after full thickness cutaneous wounding. Full thickness cutaneous wounds of control (EDA
wt/wt, 
n   6) and mutant mice (EDA
 /  and EDA
 / , n   6 and 7, respectively) mice were analyzed at 5 d after wounding by hematoxylin-eosin 
staining. Representative sections are shown. The black arrowheads indicate the wound edges. Epithelium, granulation tissue, dermis, newly 
formed epithelium, and eschar are indicated (“e,” “g,” “d,” “re”, and “sc,” respectively). The dotted rectangles in the top panels indicate the 
magnified area showed in the bottom panels. The experiment was repeated twice with similar results. Edematous granulation tissue is 
observed in the EDA
 /  wounds.T
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Figure 6.  EDA
 /  skin wounds at day 7 after wounding show abnormal healing and increased number of BrdU-positive cells. (A) Full 
thickness cutaneous wounds of control (EDA
wt/wt, n   8) and mutant mice (EDA
 /  and EDA
 / , n   8 and 9, respectively) mice were analyzed 
at 7 d after wounding. Representative sections are shown. The black arrowheads indicate the wound edges. Abbreviations are as described 
in Fig. 5. The ulcerated epithelium observed in the EDA
 /  wound is indicated as “ue.” The experiment was repeated three times with similar 
results. Wound sections of three independent experiments (eight mice per genotype in each experiments) were microscopically scored for the 
presence of ulcerative processes at day 7 after wounding. The fraction of ulcerated wounds of the EDA
 /  mice was statistically significant 
different from that of EDA
wt/wt and EDA
 /  mice (63 and 22% for EDA
 /  and EDA
wt/wt, respectively; P   0.0002 for EDA
 /  vs. EDA
wt/wt by both T
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observed in RNA samples from the brain and heart of
EDA
 /  mice (Fig. S3 available at http://www.jcb.org/cgi/
content/full/jcb.200212079/DC1).
Embryos and prepubertal EDA
 /  mice 
have normal FN levels
To determine whether the mechanisms that produced the
FN decrease were developmentally regulated, we performed
a Western blot analysis of samples prepared from mice of
different ages. The decrease in FN levels was not present
during embryonic development. It started after birth in
most of the tissues, and arrived to a plateau in 2-mo-old
mice (Fig. 4). In some tissues, the FN levels in EDA
 /  mice
were   10–20% of the amount found in EDA
wt/wt mice
(heart, blood, brain, kidney, and diaphragm), whereas the
liver showed a lesser decrease in FN levels in EDA
 /  mice,
arriving to 60–70% of the amount present in EDA
wt/wt mice.
In an attempt to determine alterations in the FN-degrada-
tive mechanisms, we performed gelatin zymography and ob-
served no variations in plasma and other tissues (brain and
heart) in the levels of matrix metalloproteinases (MMPs),
enzymes known to degrade FN (Sternlicht and Werb,
2001). Moreover, no differences were observed in the degra-
dation of in vitro translated recombinant fragments of FN
with or without the EDA exon that were incubated with tis-
sue extracts (unpublished data). Western blot analysis of tis-
sue extracts using a polyclonal anti-FN antibody did not re-
veal the presence of extra bands or any smaller degradation
product of EDA
 /  tissues, neither with a 6% nor a 12%
SDS-PAGE gel (unpublished data). Additionally, we were
unable to reproduce in vitro the reduction in FN levels after
culturing heart fibroblasts of adult mice (from 2-, 4-, and
6-mo-old animals), as the cell extracts from EDA
 /  mice
showed similar levels of FN to those of the EDA
wt/wt fibro-
blasts (unpublished data).
These experiments showed that the striking reduction in
FN protein levels in EDA
 /  mice occurred after birth. The
decrease in FN was not related to the mRNA levels present in
each tissue or to a detectable EDA
 -dependent degradation,
suggesting that alternative mechanisms should be responsible
for the decrease of tissue FN in the EDA
 /  animals.
EDA-null mice have abnormal skin wound healing
The FN present in the skin of wild-type animals does not
contain the EDA exon. However, the FN-EDA
  form is
thought to participate actively in the reepithelization process
(Clark et al., 1983; ffrench-Constant et al., 1989). To explore
the role of the EDA exon in the wound healing process, we
performed full thickness excisional skin wounds in EDA
wt/wt,
EDA
 / , and EDA
 /  mice. The wound healing process was
analyzed at 1, 3, 5, 7, 10, and 14 d after wounding. Hematox-
ylin-eosin staining of tissues from full thickness wounds dur-
ing the early phase of reepithelization (days 1 and 3) did not
show any differences in reepithelization and neovasculariza-
tion (unpublished data). During late phase (days 5 and 7), the
reepithelization and formation of granulation tissue were in-
distinguishable between EDA
 /  and EDA
wt/wt mice (Figs. 5
and 6). However, the abnormal healing process was observed
in the EDA
 /  mice. In fact, at day 5, the newly formed epi-
dermis completely covered the wound area in the EDA
 / 
mice but the border between the new epidermis and the
granulation tissue was not sharply defined as in the control
or EDA
 /  mice. Moreover, the granulation tissue of the
EDA
 /  wounds showed less compact cells with edematous-
like areas below the interface between the epidermis and the
derma granulomatous reaction (Fig. 5, bottom).
At day 7, the EDA
 /  wounds were clearly different from
those from EDA
wt/wt and EDA
 /  mice (Fig. 6 A, bottom).
In fact, the EDA
 /  wounds showed ulcerative processes at
the newly formed epidermal region level, resulting in a delay
in the reepithelization. Infiltration of inflammatory cells
such as polymorphonuclear leukocytes and macrophages
were detected by microscopic analysis of the edematous-like
and ulcerative regions, and a higher cell proliferative activity
was observed by in vivo BrdU labeling in these regions (Fig.
6 B, bottom right). On the contrary, neither EDA
wt/wt nor
EDA
 /  wounds presented a high number of BrdU-positive
cells in the area below the newly formed epidermal region
(Fig. 6 B, bottom left and center). The status of the basal
lamina in the EDA
 /  skin was similar to that of the EDA
wt/wt,
as seen by both the Azan-Mallory coloration and the spe-
cific staining of laminin in the same sections using a rabbit
polyclonal antilaminin antibody. Cell death and apoptosis-
specific analysis were performed by TUNEL and caspase-3
assays of the wound sections, respectively, and showed no
significant differences in the number of positive cells be-
tween the different genotypes (Fig. S4 available at http://
www.jcb.org/cgi/content/full/jcb.200212079/DC1). Scor-
ing of the skin healing process of three independent experi-
ments (eight 3-mo-old mice per genotype in each experi-
ment) for the presence of ulceration in the wounds showed
that EDA
 /  mice developed them 2.9 times more fre-
quently than the EDA
wt/wt mice (63% of EDA
 /  vs. 22% of
EDA
wt/wt, P   0.0002 by both the Fisher Exact test and the
 
2 test) at d 7 after wounding.
A limited number of 11-mo-old mice (five EDA
wt/wt and
six EDA
 / mice) that were subjected to the same wound
healing protocol showed an even higher proportion in the
frequency of wound ulceration in the EDA
 /  mice (83.3%
vs. 20%, EDA
 /  and EDA
wt/wt; respectively. P   0.01 by
both the Fisher Exact test and the  
2 test).
To determine whether integrin  9 1 levels were changed,
we performed a Western blot analysis of untreated skin sam-
ples and observed similar levels of integrin  9 1 among all
three genotypes (Fig. 3 E).
the Fisher Exact test and the  
2 test). There were no differences between the EDA
wt/wt and EDA
 /  scores). (B) BrdU labeling shows an increased 
number of replicating cells in the EDA
    wounds. Serial sections of the same wounds seen in A were incubated with an anti-BrdU mAb. The 
count of several microscopical fields showed that there are at least 10 times more BrdU-positive nuclei in the area below the newly formed 
epidermis in the EDA
 /  wounds when compared with EDA
wt/wt or EDA
 /  wounds. A representative field is shown. More than 50 positive nuclei 
are observed in the EDA
 /  wound (bottom right), whereas less than five positive nuclei are observed in the case of EDA
wt/wt or EDA
 /  samples 
(bottom left and center, respectively). Illustrative BrdU-labeled nuclei are indicated by white triangles. The black arrows indicate the wound edges.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
156 The Journal of Cell Biology | Volume 162, Number 1, 2003
Constitutive exclusion or inclusion of the EDA exon 
within the FN mRNA shortens the lifespan
The in vivo studies performed on rats show a critical decrease
in EDA
 /EDA
  ratio after birth, with an additional gradual
decrease of the ratio in some tissues that is correlated with the
age of the animal (Magnuson et al., 1991; Pagani et al.,
1991). We addressed the question if in EDA
 /  and EDA
 / 
mice, having no regulation of EDA splicing, the presence or
absence of the EDA exon could have an effect on their
lifespan. For this purpose, we performed a long-term experi-
ment using 139 mice (EDA
wt/wt, n   39; EDA
 / , n   47;
and EDA
 /  n   53) that were caged separately throughout
the experiment and the time of animal death was recorded.
The Kaplan-Meier graphical representation of the data is
shown in Fig. 7. It can be seen that up to 15-mo-old mice
from all the genotypes did not show any difference in sur-
vival. However, from thereon, there was a decline in the sur-
vival rate in EDA
 /  and EDA
 /  mice. At 30 mo, only
seven and eight EDA
 /  and EDA
 /  mice were alive, (10
and 12.5% survival, respectively), whereas 21 EDA
wt/wt mice
survived (53.8% survival). Log-rank test statistical analysis
indicated that both EDA
 /  and EDA
 /  mice lifespan
curves were statistically significant when compared with
EDA
wt/wt mice with P   0.0005. Postmortem external exam-
ination showed that 20–25% of the EDA
 /  mice had dif-
ferent skin hyperproliferative and spontaneous ulcerative le-
sions on their mid-dorsal skin. In case of the EDA
wt/wt and
EDA
 /  mice,  5% had any kind of skin lesions. Autopsies
were performed on naturally deceased mice of all three geno-
types. Liver tumors, intestinal obstruction, prostatic necrosis,
and pulmonary edema were the most frequently observed
features, but there was no significant difference in these pa-
thologies of the internal organs between the three genotypes.
Discussion
The first evidence of the in vivo importance of FN was dem-
onstrated by R. Hynes’s group who showed that FN-null
mice die during embryonic development (George et al.,
1993). The early embryo lethality makes it difficult to study
the biological functions of FN in the in vivo models. There-
fore, one of the best methodologies to study the function of
FN is by selective modification of the gene. Along with this
line, Sakai et al. (2001) described a mouse model lacking
pFN which showed increased neuronal apoptosis and larger
infarction areas after transient focal cerebral ischemia. In an
attempt to elucidate the role of the EDB exon, mice lacking
this exon were also produced, but showed no obvious abnor-
malities in vivo (Fukuda et al., 2002).
We have investigated the in vivo role of the EDA exon by
constructing mouse strains unable to carry out EDA exon al-
ternative splicing. The EDA
 /  strain showing constitutive
expression of the EDA exon in all tissues was obtained with-
out any modification of the coding sequences and gene
structure. This novel approach avoided the difficulties found
in a previous attempt to produce animals devoid of alterna-
tive splicing of the EDB exon in the FN gene where the
modification of the gene structure through the introduction
of a selection cassette within the introns produced an FN-
null allele (Georges-Labouesse et al., 1996). A similar phe-
nomenon has recently been observed in other genes (Lewan-
doski, 2001). None of these negative effects was observed in
our mutant mice, indicating that the insertion of loxP sites
within the flanking introns did not modify the normal pre-
mRNA transcription and processing.
Moreover, we observed no obvious embryonic mortality
nor malformation in any of the homozygous mutant mice
analyzed (EDA
 /  and EDA
 /  animals), suggesting that the
alternative splicing regulation of the EDA exon is not essen-
tial for the developmental processes or that it could be com-
pensated by other gene products. The absence of any obvious
developmental abnormality in EDA
 /  and EDA
 /  mice
suggests that the information and postulated roles for the
EDA exon obtained by using recombinant FN fragments
(Introduction) cannot be extended automatically to the in
vivo functions where more complex mechanisms are acting.
EDA
 /  mice have decreased levels of FN in all tissues
The observation of decreased levels of FN in adult EDA
 / 
mice, but not in embryos and very young mice ( 1 mo old)
suggests that different control mechanisms of FN levels are
acting before and after puberty. This decrease could be due
to one of the following explanations or a combination of
them: (1) a decrease in FN mRNA levels; (2) a decrease in
the secretion rate of FN; or (3) an increase in extracellular
degradation of FN.
A series of experiments have been performed to test which
of these mechanisms, if any, was acting in the EDA
 /  mice.
Northern blot experiments showed that the mRNA levels
were not directly related to FN protein levels (Figs. 3 and 4
and Fig. S3). Protease levels were similar to those of EDA
wt/wt,
no additional FN degradation products were seen in
EDA
 /  tissue extracts, and we were unable to see a decrease
of FN levels in in vitro cultured cells derived from adult or-
gans of EDA
 / mice. The failure to identify the precise
cause of the low FN-EDA
  levels suggests that an atypical
mechanism might be acting. One possibility is that a specific
intracellular trafficking mechanism is able to modulate the
levels of EDA
  FN forms in adult animals. This mechanism
was suggested for polarized secretion of FN forms in airway
Figure 7.  The lack of alternative splicing of the EDA exon re-
duces the lifespan of mutant mice. Both EDA
 /  and EDA
 /  mice 
showed a reduced lifespan during the 30-mo period of analysis. The 
graphic shows a Kaplan-Meier representation of the survival versus 
time of 39, 45, and 53 EDA
wt/wt, EDA
 / , and EDA
 /  mice, respec-
tively, that were housed in individual cages throughout the study. 
The results were analyzed with the Log-rank test and both the EDA
 /  
and the EDA
 /  curves were statistically significant when compared 
with the EDA
wt/wt mice (indicated by asterisks, P   0.0005).T
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epithelial cells (Wang et al., 1991). It is interesting to note
that Schwarzbauer et al (1989) have shown that the IIICS-0/
IIICS-0 dimers were not secreted. It is possible that a similar
control in the secretion mechanism could also be present for
the EDA
  subunits.
However, none of these effects was obvious in cultured fi-
broblasts from embryos and adult animals, and in the early
stages of development of mice. In fact, the decrease in the
amount of FN was evident only after 2–3 mo of age, which
is after sexual development. Alternatively, a down-regulation
of specific tissue inhibitors of MMPs in adult animals would
have as its consequence an increase in activity of specific
MMPs, a subtle change that direct gelatin zymography anal-
ysis will not detect.
Cutaneous wound healing is abnormal in EDA
 /  mice
Initially, up to 3 d after wounding, there were no differ-
ences in the healing process between the three genotypes
(EDA
wt/wt, EDA
 / , and EDA
 / ). This seems to be consis-
tent with the fact that in the first days after wounding, de-
posited FN is mainly derived from plasma (Clark et al.,
1983; ffrench-Constant et al., 1989). It was shown that
normal wound healing could be helped by the presence of
cFN (ffrench-Constant et al., 1989; Sakai et al., 2001). In
fact, in mice devoid of pFN, normal wound healing was re-
ported (Sakai et al., 2001). cFN is produced in situ 3 d after
wounding (Clark et al., 1983; ffrench-Constant et al.,
1989; Sakai et al., 2001) and a thin layer of cFN deposited
on the surface of the wound immediately after injury in
pFN-null mice (Sakai et al., 2001). Expression of cFN by
the cells found at the base and edges of the wound just be-
neath the epidermis was observed, and the presence of cFN
preceded the migration of epithelial cells that eventually
covered the wound (ffrench-Constant et al., 1989). Previ-
ous studies have also shown that FN appears in the provi-
sional matrix beneath the migrating epidermis coordinating
with the FN-receptor expression on migrating epidermal
cells (Clark et al., 1982, 1983; Grinnell, 1984). These data
correlate perfectly with our results showing that after that
period, despite the formation of granulation tissue and
neovascularization, we observed abnormal reepithelization
in EDA
 /  mice. The granulation tissue of the EDA
 / 
wounds displayed edematous regions that occur before the
ulcerative process. The subsequent epidermal ulceration
was accompanied by a proliferative stimulus with the influx
of polymorphonuclear leukocytes and macrophages, and a
delay in the healing of the wounds. Possible reasons for
these phenomena could be related to defects in the basal
lamina, a change in integrin receptor levels, and/or a defect
in the skin keratinocytes, fibroblasts, or immune system.
The basal lamina looked similar in EDA
 /  mice compared
with EDA
wt/wt mice by both Azan-Mallory coloration and
the specific immunostaining of laminin. However, we can-
not rule out minor differences in one of the other specific
proteins that are present in the basal lamina. Moreover,
similar levels of  9 1 integrin, one of the EDA receptors
(Liao et al., 2002), were observed in skin of the three geno-
types. Preliminary attempts to define differences between
the EDA
wt/wt and EDA
 /  genotypes in immune system
cells (T/B lymphocytes ratio and delayed hypersensitivity)
and in the characteristics of fibroblasts (in vitro cell migra-
tion, cell adhesion, and duplication time) failed to show sig-
nificant differences. However, it remains to be seen if the
localization pattern of the integrin receptors or their signal-
ing have been affected in the mutant mice.
The increase in ulceration in the EDA
 /  wounds could
be the result of a higher rate of cell death in the skin of the
mice during wound closure. This does not seem to be the
case as the number of positive cells between the EDA
wt/wt,
EDA
 / , and EDA
 /  wounds in the granulation tissue
were similar in the area devoid of ulceration by both
TUNEL and caspase-3 assay.
On the basis of these considerations and the data described
in Results, we conclude that FN containing the EDA seg-
ment plays an essential role in the organization of the granu-
lation tissue and probably in epidermal cell migration, either
directly or by interaction with other ECM components.
EDA
 /  and EDA
 /  mouse strains have 
a shorter lifespan
It has been shown that deficiency of SH2-containing inosi-
tol-5-phosphatase, lysosomal acid lipase, and DNA topo-
isomerase III  had no consequences in embryonic develop-
ment, but shortens the lifespan of the animals (Helgason et
al., 1998; Du et al., 2001; Kwan and Wang, 2001). The
shortened lifespan could be due to the changes in biological
processes, which require the presence of the investigated
protein during aging.
In the case of the FN mice, we showed that the absence of
regulation of the EDA exon affects the lifespan of mutant
animals. In normal animals, a dramatic change in the
EDA
 /EDA
  ratio is observed after birth and a gradual de-
crease of EDA inclusion is observed in the tissues that in-
creases with the age of the animal (Magnuson et al., 1991;
Pagani et al., 1991). Alternative splicing of FN is regulated
at both the extracellular (ffrench-Constant, 1995; Korn-
blihtt et al., 1996; Boyle et al., 2000) and the molecular lev-
els (Mardon et al., 1987; Lavigueur et al., 1993; Caputi et
al., 1994; Muro et al., 1999). The mutant EDA
 /  and
EDA
 /  mice have no regulation of splicing of the EDA exon.
It was possible that some biological processes that required
specific EDA
 /EDA
  ratios of FN were altered because of
the absence of regulation of EDA splicing. In fact, this was
shown in this paper for the specific case of cutaneous wound
healing in the EDA
 /  mice. Furthermore, the low healing
efficiency was exacerbated in older mice. In a similar fash-
ion, other maintenance and tissue repair mechanisms could
be affected, and the cumulative lower efficiency may result
in a decrease in the lifespan of mutant animals. In the spe-
cific case of the EDA
 /  mice, due to the dramatic reduction
in FN levels in most organs, it remains unclear whether the
shortened lifespan seen in EDA
 /  mice was due to a change
in FN quantity and/or quality. Although no significant dif-
ferences have been reported on the lifespan of c129 and
C57BL/6 (Smith et al., 1973; Goodrick, 1975; Kunstyr and
Leuenberger, 1975), we cannot formally rule out that the
differences in chromosome background at the FN EDA lo-
cus (C57BL/6 for the EDA
wt/wt and c129 with one or two
loxP sites for EDA
 /  and EDA
 / , respectively) could be
responsible for the observed differences in lifespan.T
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In summary, we generated mice devoid of regulated splic-
ing at the EDA exon of the FN gene. Surprisingly, both
mouse strains showed that the alternative splicing at the
EDA exon was dispensable during embryonic development,
but it was necessary for a normal lifespan. Moreover, mice
unable to incorporate the EDA exon in the FN protein dis-
played abnormal skin wound healing. On the other hand,
mice having constitutive inclusion of the EDA exon showed
an important decrease in the FN levels in all tissues.
The results presented here are important for three reasons:
first, we presented a novel method to study the function of
protein isoforms; second, we added valuable information re-
garding the function of the FN isoforms; and third, we
showed that changes in the regulation of splicing are respon-
sible for subtle changes in the phenotype that may be
present, but undetected, in human pathologies.
Materials and methods
Mice
C57BL/6 mice were bred at the International Centre for Genetic Engineer-
ing and Biotechnology animal house or purchased from Harlan, Italy. All
mice were housed in rooms at 25 C with 12-h light/dark cycles. Mice were
fed with standard food and water ad libitum. In all experiments, mice were
males and age-matched, except in the aging experiment in which both
males and females were used. Blood was drawn by puncture of the inter-
nal maxillary artery.
Generation of homozygous EDA mutant mice
Cloning of the murine genomic EDA region and targeting construct. A 13-kbp
genomic clone containing the EDA exon region of the murine FN gene
was isolated from a 129/Sv   DashII library (a gift of G. Friedrich, Fred
Hutchinson Cancer Research Center, Seattle, WA). The exon–intron struc-
ture and restriction map of this fragment was determined by restriction en-
zyme mapping followed by Southern blot analysis using individual exons
as probes, which were PCR amplified from the human FN cDNA. Both the
5  and 3  splice sites of the EDA exon were modified by PCR-directed mu-
tagenesis as described previously (Muro et al., 1998). In brief, the 5  splice
site was mutated to the 5  consensus (5 CAGgtaagt3 ) and the 3  splice site
was replaced by that of the constitutively spliced-in second exon of the
apolipoprotein AI gene, which matches exactly the 3  consensus (see On-
line supplemental material).
Our targeting construct consisted of 11.5 kbp of mouse genomic DNA.
Neomycin (Neo) and diphtheria toxin (DTA) genes were used as positive
and negative selection markers, respectively, for the first round of recombi-
nation. Three loxP sites were included in the targeting construct flanking
the Neo-Thymidine Kinase (TK) cassette and the EDA exon.
The targeting construct was electroporated into ES cells, and 350 G418-
resistant clones were genotyped by Southern blot hybridization of NcoI–
NdeI-digested DNA using the 5  external probe (Fig. 1 A). Eight recombinant
clones were obtained, and three of them underwent a second step of recom-
bination by transient expression of the CRE recombinase (by transient trans-
fection of the pBS185 plasmid; a gift of B. Sauer, Stowers Institute for Medi-
cal Research, Kansas City, MO) and selection in the presence of gancyclovir.
Two recombinant clones having the deleted Neo-TK cassette and the loxP-
flanked EDA were selected and amplified. More detailed Southern blot anal-
ysis and sequencing of the PCR-amplified genomic EDA region of two re-
combinant clones was done to confirm the introduction of the optimized 3 
and 5  splice sites and the loxP sites flanking the EDA exon in one of the FN
alleles. Both clones were used in order to obtain chimeras. Male chimeras
obtained by microinjection of C57BL/6 blastocyst were mated to C57BL/6
females in order to generate heterozygous animals (F1 mice).
The F1 offsprings were analyzed for the transmission of the modified
EDA exon within the FN gene. HindIII-digested DNA from tail biopsies
from the agouti progeny was genotyped by Southern blot using the EDA  
1 internal probe (Fig. 1, A and B). F1 heterozygous offsprings were mated
with C57BL/6 mice to obtain F2 generation, which were then mated to
each other to produce EDA
 /  mice (inclusion of the modified EDA exon
in both the FN alleles). F1 EDA
 /wt mice were mated with a CRE-recombi-
nase transgenic mice (on a C57BL/6 background) to obtain EDA
 /wt prog-
eny (F2) that were subsequently mated to obtain EDA
 /  animals.
Preparation of RNA from adult mouse and embryonic tissues
Total cellular RNA from various tissues was prepared by the guanidinium
thiocyanate method (Chomczynski and Sacchi, 1987), quantitated by mea-
suring absorbance at 260 and 280 nm, and RNA integrity was confirmed
by running the samples on 1% agarose formaldehyde gels. For embryonic
RNA samples, embryos were dissected under a stereomicroscope (model
SMZ-10; Nikon) and tissues were pooled from five to six embryos (13.5 d
p.c.). RNA was prepared using RNAZOL TM B (Biotecx Lab) according to
the manufacturer’s instructions.
mRNA analysis by Northern blot and radioactive RT-PCR
10–20  g of total RNA from different tissues was denatured and run on
a 1.2% agarose formaldehyde gel, blotted onto a nylon membrane (Hy-
bond-N; Amersham Biosciences), and stained with a methylene blue solu-
tion to verify the efficiency of the transfer. The membrane was prehybrid-
ized in ExpressHyb
TM hybridization solution (CLONTECH Laboratories,
Inc.) and hybridized with the radioactive-labeled probe. It was exposed
overnight using BIOMAX MS films (Kodak), and quantification of the ra-
dioactive signal was done with a phosphorimager (Canberra-Packard). FN
cDNAs were analyzed as described in the Materials and methods section
of the online supplemental material.
Preparation of protein extracts
Adult mouse tissues were surgically removed, homogenized in lysis buffer
(150 mM NaCl, 50 mM Tris-HCl, pH 8, 1% wt/vol NP-40, and 2  com-
plete protease inhibitor cocktail [Boehringer] with a polytron [Ultra-Turrax
T8; Boehringer]), and analyzed by SDS-PAGE after protein determination
using the Bradford assay (protein assay kit; Bio-Rad Laboratories).
In the case of embryos, tissues from five to six embryos per genotype
were surgically removed with the help of a stereomicroscope and pooled.
The protein extracts were prepared by sonication in 150  l of lysis buffer.
Western blot analysis
50  g protein extracts were run on a 6%, 12%, and a gradient of 5–17%
SDS-PAGE gels. The proteins were blotted onto a nitrocellulose membrane,
incubated with the first and secondary antibodies, and the reaction was de-
veloped using the ECL system (Amersham Biosciences). The following pri-
mary antibodies were used: anti–human FN goat polyclonal antibody
(Sigma-Aldrich), anti–human EDA mouse mAb 3E2 (Sigma-Aldrich), anti–
 9-integrin rabbit polyclonal (a gift from D. Sheppard, University of San
Francisco, San Francisco, CA), anti– 1-integrin rabbit polyclonal (Santa
Cruz Biotechnology, Inc.), and the anti– -tubulin mAb E7 (Developmental
Studies Hybridoma Bank, University of Iowa) antibodies. Densitometry
analysis was performed by using the Versa-Doc Analyzer (Bio-Rad Labora-
tories) with Quantity One software (Version 4; Bio-Rad Laboratories).
Immunofluorescence studies of MEF
Embryonic fibroblasts (13.5 d) from EDA
wt/wt, EDA
 / , and EDA
 /  mice
were cultured on coverslips for 24 h. Cells were washed and fixed with 4%
vol/vol PFA in PBS, permeabilized with 0.5% vol/vol Triton X-100 in PBS,
and blocked. Cells were incubated with anti–human FN goat polyclonal
antibody and in parallel with goat normal serum or with the mAb 3E2, and
incubated with fluorescein-labeled rabbit anti–goat IgG (DakoCytomation)
or with rhodamine-labeled rabbit anti–mouse IgG (DakoCytomation), re-
spectively. Negative controls were performed with cells incubated directly
with the fluorescent antibody. The analysis of the immunofluorescence
was done by using a confocal laser scanning microscope (model Axiovert
100 M; Carl Zeiss MicroImaging, Inc.).
Wound healing
Wounding and wound closure measurements. Full thickness skin wounds
were done in 2–3-mo-old male mice (n   12 per genotype) in two inde-
pendent experiments. Genotypes were blind to the researcher and ob-
server. In brief, animals previously anesthetized with Avertin, were shaved,
swabbed with 70% ethanol and two circular, full thickness excisional
wounds (5-mm diam, separated by 10 mm) were created on their backs,
by excising the skin and panniculus carnosus. The mice were housed indi-
vidually. For macroscopic analysis, mice were monitored daily and
wounds were photographed and measured at each time point (0, 3, 5, 7,
10, and 14 d) to analyze the healing process.
Preparation, analysis, and histology of wound tissues. For histology of
wounds, six 3-mo-old male mice from each genotype were killed at each
time point (1, 3, 5, 7, 10, and 14 d), and their wounds were harvested by
complete excision including the 3 mm of the epithelial margins. Wounds
were immediately fixed in 2% formaldehyde in PBS containing 0.02% NP-T
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40 at 4 C for 3 h. They were placed in 2% formaldehyde in PBS, left over-
night in the cold, and paraffin embedded. 3–5-mm sections from the mid-
dle of the wounds were stained with hematoxylin-eosin and analyzed by
light microscopy. The analysis of the wound tissue at day 7 was performed
in groups of eight mice per genotype in three independent experiments
showing similar results. For basal lamina immunohistochemistry of the
wounds, we used the polyclonal antilaminin antibody from Biogenex as
described by the manufacturers.
BrdU incorporation. To allow the analysis of the cell proliferation in the
wounds, the nucleoside analogue BrdU (250 mg/kg of body weight) was
injected i.p. 2 h before the animals were killed (eight animals per each ge-
notype, day 7 after wounding). Samples were prepared as described in the
previous paragraph. Incorporation of i.p.-injected BrdU into DNA of repli-
cating cells was analyzed using anti-BrdU mAbs conjugated with alkaline
phosphatase as described by the manufacturer (BrdU-labeling and detec-
tion kit II; Roche). The day 7 time point with BrdU labeling was also per-
formed with six 11-mo-old male mice per genotype. Representative data
are shown in the figures.
Statistical methods
Data analyses were performed with the use of the software package
GraphPad PRISM, version 2.0. Data were summarized with the mean as a
measure of central tendency and the standard error as a measure of disper-
sion. The differences in proportions between the wild-type and mutant
mice were assessed by using the  
2 and the Fisher Exact test. A p-value of
0.05 was chosen as the limit of statistical significance. Log-rank test statis-
tical analysis was used to evaluate the survival curves.
Online supplemental material
The online supplemental material section contains the rationale used for
the optimization of splice sites and RNAse protection analysis of liver sam-
ples from control and mutant mice (see Figs. S1 and S2, respectively). The
experimental analysis of allele frequencies, offspring, and embryos is also
described. Northern blot analysis and TUNEL and caspase-3 analysis of
skin wounds are shown in Figs. S3 and S4, respectively. Online sup-
plemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200212079/DC1.
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